Craig Eckfeldt, MD, PhD

Developing novel targeted and immune therapy approaches for acute myeloid leukemia (AML). The goal of the research in our lab is to investigate the genetics and signaling pathways that drive acute myeloid leukemia (AML) to provide a foundation for the development of novel targeted and immune treatment approaches for AML. Our research is focused on identifying the critical pathways that drive AML growth and survival, evaluating the effects of targeted therapies in preclinical cancer models, and studying how targeted therapies influence the susceptibility of cancer cells to immune therapies such as Natural Killer (NK) cell immunotherapy, an area of institutional expertise. We utilize cutting edge molecular genetic techniques and genetically engineered and humanized mouse models including patient-derived AML xenografts for our preclinical studies. Ultimately, we aim to translate our findings to human clinical trials for cancer patients.